ERBB2 and neoplasm: HER2 is able to activate both PI3K and MAPK pathways as upstream receptor tyrosine kinase upon dimerization with ErbB family receptor members 32 and, therefore, our result on the presence of HER2‐positive tumor samples with relatively less to no activation of the PI3K and/or MAPK pathways was unexpected.